Literature DB >> 17654686

Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes.

Anwar N Mohamed1, Gail Bentley, Michelle L Bonnett, Jeff Zonder, Ayad Al-Katib.   

Abstract

We identified 120 multiple myeloma (MM) cases with satisfactory cytogenetic evaluation and abnormal karyotypes. Hyperdiploid karyotype was found in 77 cases (64%), hypodiploid in 30 cases (25%), and the remaining 13 cases (11%) had a pseudodiploid karyotype. The most common numerical abnormalities were gains of chromosomes 15, 9, 3 followed by chromosomes 19, 11, 7, 21, and 5. Whole chromosome losses were also frequent involving primarily chromosomes X/Y, 8, 13, 14, and 22. Most cases showed also structural rearrangements leading to del(1p), dup(1q), del(5q), del(6q), del(8p), del(9p), del(13q), and del(17p). Chromosome 13/13q deletion was found in 52% of cases; complete loss of 13 was observed in 73% of cases, whereas 27% had interstitial deletions. In addition, 13/13q deletions occurred in 75% of nonhyperdiploid myeloma but only 39% of the hyperdiploid had 13/13q deletions. Translocations affecting 14q32/IGH region was seen 40 cases; t(11;14)(q13;q32) in 17 cases, t(14;16)(q32;q23) and t(8;14)(q24;q32) in three cases each, and t(6;14)(p21;q32) and t(1;14)(q21;q32) in two cases each. The remaining 14q32 translocations had various t(V;14) partners or of an undetermined origin. Remarkably, the 14q32/IGH translocations were less frequent in the hyperdiploid karyotypes than the nonhyperdiploid karyotypes (17 vs. 63%). Fourteen cases showed break at 8q24/CMYC site; seven of those had Burkitt's-type translocations. Our results revealed that conventional cytogenetics remains an important tool in elucidating the complex and divers genetic anomalies of MM. Cytogenetics identifies two distinct groups of MM, hyperdiploid and nonhyperdiploid, and establishes the presence of prognostic chromosomal markers such as 13/13q, 17p, 8q24, and 16q aberrations.

Entities:  

Mesh:

Year:  2007        PMID: 17654686     DOI: 10.1002/ajh.20998

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  15 in total

1.  Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases.

Authors:  Cigdem Aydin; Turgay Ulas; Ceren Hangul; Orhan Kemal Yucel; Utku Iltar; Ozan Salim; Deniz Ekinci; Sibel Berker Karauzum
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-25       Impact factor: 0.900

2.  New complex chromosome abnormalities in multiple myeloma associated with a poor prognosis: a case report.

Authors:  Agnes C Fett-Conte; Andréa B Carvalho-Salles; Cristina B Vendrame; Patrícia Pedrassa; Paula C Freitas; Marileila Varella-Garcia
Journal:  Leuk Res       Date:  2012-04-12       Impact factor: 3.156

3.  IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.

Authors:  Alexandra Valera; Olga Balagué; Luis Colomo; Antonio Martínez; Jan Delabie; Lekidelu Taddesse-Heath; Elaine S Jaffe; Elías Campo
Journal:  Am J Surg Pathol       Date:  2010-11       Impact factor: 6.394

4.  Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.

Authors:  J R Sawyer; E Tian; J D Shaughnessy; J Epstein; C M Swanson; C Stangeby; C L Hale; L Parr; M Lynn; G Sammartino; J L Lukacs; C Stein; C Bailey; M Zangari; F E Davies; F Van Rhee; B Barlogie; G J Morgan
Journal:  Leukemia       Date:  2016-10-03       Impact factor: 11.528

5.  Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach.

Authors:  Angela Baker; Esteban Braggio; Susanna Jacobus; Sungwon Jung; Dirk Larson; Terry Therneau; Angela Dispenzieri; Scott A Van Wier; Gregory Ahmann; Joan Levy; Louise Perkins; Seungchan Kim; Kimberly Henderson; David Vesole; S Vincent Rajkumar; Diane F Jelinek; John Carpten; Rafael Fonseca
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

6.  Frequent down regulation of the tumor suppressor gene a20 in multiple myeloma.

Authors:  Katharina Troppan; Sybille Hofer; Kerstin Wenzl; Markus Lassnig; Beata Pursche; Elisabeth Steinbauer; Marco Wiltgen; Barbara Zulus; Wilfried Renner; Christine Beham-Schmid; Alexander Deutsch; Peter Neumeister
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

7.  Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.

Authors:  B A Walker; C P Wardell; A Brioli; E Boyle; M F Kaiser; D B Begum; N B Dahir; D C Johnson; F M Ross; F E Davies; G J Morgan
Journal:  Blood Cancer J       Date:  2014-03-14       Impact factor: 11.037

8.  NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma.

Authors:  Ye Yang; Wen Zhou; Jiliang Xia; Zhimin Gu; Erik Wendlandt; Xin Zhan; Siegfried Janz; Guido Tricot; Fenghuang Zhan
Journal:  Oncotarget       Date:  2014-12-15

9.  Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles.

Authors:  Yingxiang Li; Xujun Wang; Haiyang Zheng; Chengyang Wang; Stéphane Minvielle; Florence Magrangeas; Hervé Avet-Loiseau; Parantu K Shah; Yong Zhang; Nikhil C Munshi; Cheng Li
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

10.  Conventional and molecular cytogenetic analyses in Turkish patients with multiple myeloma.

Authors:  Beyhan Aras Durak; Olga Meltem Akay; Gülçin Sungar; Güney Bademci; Vahap Aslan; Jülide Caferler; Muhsin Ozdemir; Oğuz Cilingir; Sevilhan Artan; Zafer Gülbaş
Journal:  Turk J Haematol       Date:  2012-06-15       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.